ATE174629T1 - Herstellung von proteinen mittels protein 7b2 - Google Patents

Herstellung von proteinen mittels protein 7b2

Info

Publication number
ATE174629T1
ATE174629T1 AT92923809T AT92923809T ATE174629T1 AT E174629 T1 ATE174629 T1 AT E174629T1 AT 92923809 T AT92923809 T AT 92923809T AT 92923809 T AT92923809 T AT 92923809T AT E174629 T1 ATE174629 T1 AT E174629T1
Authority
AT
Austria
Prior art keywords
protein
pct
expressing
vivo
sec
Prior art date
Application number
AT92923809T
Other languages
English (en)
Inventor
Gerardus Julianus Mari Martens
Bhabatosh Chaudhuri
Christine Stephan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE174629T1 publication Critical patent/ATE174629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT92923809T 1991-11-29 1992-11-27 Herstellung von proteinen mittels protein 7b2 ATE174629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9102009A NL9102009A (nl) 1991-11-29 1991-11-29 Produktie van bioactieve peptiden met recombinante cellen.

Publications (1)

Publication Number Publication Date
ATE174629T1 true ATE174629T1 (de) 1999-01-15

Family

ID=19859984

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92923809T ATE174629T1 (de) 1991-11-29 1992-11-27 Herstellung von proteinen mittels protein 7b2

Country Status (11)

Country Link
US (2) US5708140A (de)
EP (1) EP0614490B1 (de)
JP (1) JPH07501448A (de)
AT (1) ATE174629T1 (de)
AU (1) AU675919B2 (de)
CA (1) CA2123567A1 (de)
DE (1) DE69227921D1 (de)
FI (1) FI942442L (de)
HU (1) HUT67739A (de)
NL (1) NL9102009A (de)
WO (1) WO1993011248A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025681A1 (en) * 1992-06-11 1993-12-23 New York University A cytoplasmic chaperonin and methods of making and using it
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
ATE195347T1 (de) * 1992-10-02 2000-08-15 Res Corp Technologies Inc Methoden der erhöhung der sekretion von überexpremierten proteinen
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
JPH09173078A (ja) * 1995-09-14 1997-07-08 Tadayuki Imanaka 分子シャペロンを用いる蛋白質の製造方法
JP2000512487A (ja) * 1996-05-14 2000-09-26 スミスクライン・ビーチャム・コーポレイション 新規化合物
AU5602100A (en) 1999-06-09 2000-12-28 Arch Development Corporation Recombinant prion-like genes and proteins and materials and methods comprising same
AU2001261242B2 (en) * 2000-05-03 2006-12-14 Expressive Constructs, Inc. A method for improving recombinant protein stability and solubility
JP4528460B2 (ja) * 2000-06-30 2010-08-18 株式会社東芝 半導体素子
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
EP1624886A2 (de) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Verfahren zur erhöhung der zell- und gewebevariabilität
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
FR3008713B1 (fr) * 2013-07-18 2016-11-25 Commissariat Energie Atomique Procede d'extraction et de purification d'acides nucleiques et tampons mis en œuvre

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8702590A (nl) * 1987-10-30 1989-05-16 Stichting Katholieke Univ Eiwit 7b2 alsmede recombinant dna en cdna, mrna, en antilichamen voor 7b2 en werkwijze voor het detecteren van 7b2.
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells

Also Published As

Publication number Publication date
JPH07501448A (ja) 1995-02-16
HU9401604D0 (en) 1994-09-28
DE69227921D1 (de) 1999-01-28
FI942442A0 (fi) 1994-05-25
US5804417A (en) 1998-09-08
HUT67739A (en) 1995-04-28
EP0614490A1 (de) 1994-09-14
AU675919B2 (en) 1997-02-27
FI942442A7 (fi) 1994-07-25
WO1993011248A1 (en) 1993-06-10
US5708140A (en) 1998-01-13
AU2946192A (en) 1993-06-28
NL9102009A (nl) 1993-06-16
CA2123567A1 (en) 1993-06-10
EP0614490B1 (de) 1998-12-16
FI942442L (fi) 1994-07-25

Similar Documents

Publication Publication Date Title
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
DE69434447D1 (de) Für die gentherapie verwendbare plasmide
DE69323879D1 (de) Herstellung von rekombinanten, menschlichem lactoferrin
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
ES8306324A1 (es) "proceso para la produccion microbiana de interferon fibroblasto humano".
ATE358176T1 (de) Menschliche dnase
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
NL189092C (nl) Hybride menselijke leukocytinterferons, dubbelstrengs dna dat hiervoor codeert, expressievector, transformant micro-organisme, werkwijzen ter bereiding daarvan en farmaceutisch preparaat.
DE69123361D1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
ATE207758T1 (de) Verwendung von igf-1
DE59610632D1 (de) Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE175237T1 (de) Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung.
AU669149B2 (en) Expression signal-peptide-free staphylokinases
ATE315091T1 (de) Modifizierte zellen auf der basis des betain- katabolismus, herstellung und verwendung insbesondere zur herstellung von metaboliten oder enzymen
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE204018T1 (de) Zellwachstumsinhibitoren
DE69728654D1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
AU637589B2 (en) Ancrod proteins, their production and use
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
DE69434072D1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
SE9300509D0 (sv) Peg treatment
ATE452139T1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind
AU5110390A (en) Cdna coding for placental protein 9 (pp9), the isolation and use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties